RATIONALE: Dopamine D(2)-like agonists maintain responding when substituted for cocaine in laboratory animals. However, these effects appear to be mediated by an interaction with stimuli that were previously paired with cocaine reinforcement (CS). OBJECTIVES: To evaluate the extent to which the pramipexole-maintained and pramipexole-induced responding are influenced by cocaine-paired stimuli. METHODS: Rats were trained to nosepoke for cocaine under fixed ratio 1 (FR1) or progressive ratio (PR) schedules of reinforcement. In FR1-trained rats, pramipexole was substituted for cocaine with injections either paired with CSs, or delivered in their absence. The capacity of experimenter-administered pramipexole to induce FR1 and PR responding for CS presentation was evaluated. The effects of altering stimulus conditions, as well as pretreatments with D(2)- (L: -741,626) and D(3)-preferring (PG01037) antagonists on pramipexole-induced PR responding were also evaluated. RESULTS: When substituted for cocaine, pramipexole maintained responding at high rates when injections were paired with CSs, but low rates when CSs were omitted. Similarly, experimenter-administered pramipexole induced dose-dependent increases in FR1 or PR responding, with high rates of responding observed when the CS was presented, and low rates of responding when CS presentation was omitted. D(2) and D(3) antagonists differentially affected pramipexole-induced PR responding, with L: -741,626 and PG01037 producing rightward, and downward shifts in the dose-response curve for CS-maintained responding, respectively. CONCLUSIONS: These data indicate that pramipexole is capable of enhancing the reinforcing effectiveness of conditioned stimuli, and raise the possibility that similar mechanisms are responsible for the increased occurrence of impulse control disorders in patients being treated with pramipexole.
RATIONALE: Dopamine D(2)-like agonists maintain responding when substituted for cocaine in laboratory animals. However, these effects appear to be mediated by an interaction with stimuli that were previously paired with cocaine reinforcement (CS). OBJECTIVES: To evaluate the extent to which the pramipexole-maintained and pramipexole-induced responding are influenced by cocaine-paired stimuli. METHODS:Rats were trained to nosepoke for cocaine under fixed ratio 1 (FR1) or progressive ratio (PR) schedules of reinforcement. In FR1-trained rats, pramipexole was substituted for cocaine with injections either paired with CSs, or delivered in their absence. The capacity of experimenter-administered pramipexole to induce FR1 and PR responding for CS presentation was evaluated. The effects of altering stimulus conditions, as well as pretreatments with D(2)- (L: -741,626) and D(3)-preferring (PG01037) antagonists on pramipexole-induced PR responding were also evaluated. RESULTS: When substituted for cocaine, pramipexole maintained responding at high rates when injections were paired with CSs, but low rates when CSs were omitted. Similarly, experimenter-administered pramipexole induced dose-dependent increases in FR1 or PR responding, with high rates of responding observed when the CS was presented, and low rates of responding when CS presentation was omitted. D(2) and D(3) antagonists differentially affected pramipexole-induced PR responding, with L: -741,626 and PG01037 producing rightward, and downward shifts in the dose-response curve for CS-maintained responding, respectively. CONCLUSIONS: These data indicate that pramipexole is capable of enhancing the reinforcing effectiveness of conditioned stimuli, and raise the possibility that similar mechanisms are responsible for the increased occurrence of impulse control disorders in patients being treated with pramipexole.
Authors: Gregory T Collins; Diane M Calinski; Amy Hauck Newman; Peter Grundt; James H Woods Journal: J Pharmacol Exp Ther Date: 2008-02-27 Impact factor: 4.030
Authors: Maram A T M Khaled; Keyghobad Farid Araki; Beth Li; Kathleen M Coen; Peter W Marinelli; Jenô Varga; József Gaál; Bernard Le Foll Journal: Int J Neuropsychopharmacol Date: 2009-12-09 Impact factor: 5.176
Authors: Gregory T Collins; Andrew Truccone; Faiza Haji-Abdi; Amy Hauck Newman; Peter Grundt; Kenner C Rice; Stephen M Husbands; Benjamin M Greedy; Cecile Enguehard-Gueiffier; Alain Gueiffier; Jianyong Chen; Shaomeng Wang; Jonathan L Katz; David K Grandy; Roger K Sunahara; James H Woods Journal: J Pharmacol Exp Ther Date: 2009-01-09 Impact factor: 4.030
Authors: Gregory T Collins; Paul Butler; Chris Wayman; Sian Ratcliffe; Paul Gupta; Geoffrey Oberhofer; S Barak Caine Journal: Behav Pharmacol Date: 2012-06 Impact factor: 2.293
Authors: Mikhail N Koffarnus; Gregory T Collins; Kenner C Rice; Jianyong Chen; James H Woods; Gail Winger Journal: Behav Pharmacol Date: 2012-08 Impact factor: 2.293
Authors: Maram A T M Khaled; Abhiram Pushparaj; Patricia Di Ciano; Jorge Diaz; Bernard Le Foll Journal: Neuropsychopharmacology Date: 2014-07-07 Impact factor: 7.853
Authors: Simon Loiodice; Poppy Winlow; Sarah Dremier; Etienne Hanon; David Dardou; Omar Ouachikh; Aziz Hafidi; Andre Nogueira da Costa; Franck Durif Journal: Psychopharmacology (Berl) Date: 2016-09-10 Impact factor: 4.530
Authors: Thomas F Newton; Colin N Haile; James J Mahoney; Ravi Shah; Christopher D Verrico; Richard De La Garza; Thomas R Kosten Journal: Psychiatry Res Date: 2015-07-29 Impact factor: 3.222